Brought to you by 
GPC Biotech and Pharmion co-develop satraplatin;ends
07 Aug 2008
Executive Summary
GPC Biotech (cancer therapeutics) has licensed to Pharmion (hematology and oncology) exclusive rights to commercialize the Phase III cancer candidate satraplatin for hormone refractory prostate cancer (HRPC) in Europe, Turkey, the Middle East, Australia, and New Zealand.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com